Rosuvastatin

Etki Mekanizması

Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for hepatic cholesterol synthesis. By blocking this enzyme, rosuvastatin reduces intracellular cholesterol in hepatocytes, which triggers upregulation of LDL receptor expression on the liver cell surface. The increased density of LDL receptors enhances clearance of LDL cholesterol and its precursors (VLDL and IDL) from the bloodstream. Rosuvastatin has the highest binding affinity for HMG-CoA reductase among all available statins, which accounts for its superior potency. Beyond lipid lowering, rosuvastatin exerts pleiotropic effects that contribute to cardiovascular protection: improvement of endothelial function via increased nitric oxide bioavailability, reduction of vascular inflammation (lowering hsCRP by 30-50%), stabilization of atherosclerotic plaques, decreased oxidative stress, and modest antithrombotic effects. In the context of AAS use, rosuvastatin counteracts the characteristic lipid derangement pattern caused by androgens -- namely suppressed HDL cholesterol and elevated LDL cholesterol -- by directly reducing LDL production and, to a lesser extent, raising HDL through unclear mechanisms thought to involve apolipoprotein A-I upregulation.